Home » Stocks » ORPH

Orphazyme A/S (ORPH)

Stock Price: $13.84 USD 0.19 (1.39%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 485.96M
Revenue (ttm) n/a
Net Income (ttm) -64.09M
Shares Out 34.66M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $13.84
Previous Close $13.65
Change ($) 0.19
Change (%) 1.39%
Day's Open 13.78
Day's Range 13.04 - 13.84
Day's Volume 5,255
52-Week Range 8.96 - 13.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

Orphazyme A/SInvestor news                                                                                                        No. 01/2021                                                   ...

Business Wire - 3 weeks ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...

GlobeNewsWire - 4 weeks ago

Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerati...

GlobeNewsWire - 1 month ago

Orphazyme A/SCompany announcement                                                                                         No. 72/2020Inside informationCompany Registration No. 32266355

GlobeNewsWire - 1 month ago

Global executive team expanding to support growth plans with three U.S.-based leaders

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...

Other stocks mentioned: CYTR
GlobeNewsWire - 2 months ago

­­Orphazyme A/SCompany announcement                                                                                        No. 70/2020                                                          ...

GlobeNewsWire - 3 months ago

Orphazyme A/SCompany announcement                                                                                        No. 67/2020                                                            ...

Seeking Alpha - 3 months ago

Due to unfortunate timing, Orphazyme listing on NASDAQ did not go smoothly.

GlobeNewsWire - 3 months ago

Copenhagen, Denmark, October 2, 2020 – Orphazyme A/S (ORPHA; ORPH) (“Orphazyme”), CVR no. 32266355, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the tr...

GlobeNewsWire - 3 months ago

Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) ...

Other stocks mentioned: OZYMF
Seeking Alpha - 4 months ago

Orphazyme has filed to raise $100 million in a U.S. IPO.

Other stocks mentioned: OZYMF
GlobeNewsWire - 4 months ago

Orphazyme A/SCompany announcement                                                                                        No. 50/2020                                                            ...

Other stocks mentioned: OZYMF
Market Watch - 4 months ago

Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.

Other stocks mentioned: OZYMF

About ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.

Industry
Pharmaceutical Preparation Manufacturing
IPO Date
Sep 29, 2020
CEO
Kim Stratton
Employees
114
Stock Exchange
NASDAQ
Ticker Symbol
ORPH
Full Company Profile

Financial Performance

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Orphazyme stock is "Strong Buy." The 12-month stock price forecast is 21.00, which is an increase of 51.73% from the latest price.

Price Target
$21.00
(51.73% upside)
Analyst Consensus: Strong Buy